Loading organizations...
Widwin Investment operates as a venture capital firm, strategically deploying capital into early and growth-stage companies. Based in Seoul, the firm targets diverse sectors, including healthcare and software. Its approach provides financial backing and strategic guidance, enabling portfolio companies to navigate complex growth phases and achieve significant market presence.
Established in 2008, Widwin Investment was founded based on the recognition of demand for specialized investment partners within South Korea's dynamic technological and industrial landscape. Its inception reflected a commitment to identifying high-potential ventures, equipping them with essential resources for sustained development and market success.
It partners with ambitious companies seeking capital and expertise to accelerate market penetration and scale operations. Widwin Investment's vision fosters a robust innovation ecosystem by actively engaging with its portfolio companies. It aims to empower visionary entrepreneurs, contributing to forward-looking economic advancement.
Widwin Investment has 2 tracked investments across 2 companies. The latest tracked deal is $47.0M Series B in PineTree Therapeutics in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 28, 2025 | PineTree Therapeutics | $47.0M Series B | — | Atinum Investment, Yohan KIM, Gauss Capital Management, Korea Investment Partners, Samho Green Investment, SJ Investment Partners, Smilegate Investment, S&S Investment, Stic Ventures, SV Investment |
| Feb 28, 2022 | BIORCHESTRA | $45.0M Series C | — | Chong KUN Dang Holdings, Chong KUN Dang Pharmaceutical, Daily Partners, E&venture Partners, GS Holdings, IMM Investment, LSK Investment, NH Investment & Securities, Quantum Ventures Korea, SBI Investment, Smilegate Investment, Stick Investment |
